NCT05473325 (BRANCH-P) is a clinical trial in Diabetes, sponsored by Willows Health.

Who is sponsoring NCT05473325?

NCT05473325 is sponsored by Willows Health.

What condition does NCT05473325 study?

NCT05473325 studies Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease, Cardiovascular Diseases, Mononucleosis, Flu, Heart Diseases, HIV Infections, AIDS and Infections, Bulimia, Chest Infections, Arthritis, Leukaemia, Alcoholic Liver Disease, Allergies, Alzheimer Disease, Appendicitis, Eczema, Bronchitis, Cellulitis, Cirrhosis, Depression, Gout, High Cholesterol, Indigestion, Obesity, Osteoporosis.

Is NCT05473325 still recruiting?

NCT05473325 is currently status unknown. Last updated 15 August 2022.

Last reviewed 2022-08-15 · How we verify

NCT05473325: BRANCH-P

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)

Status unknown Last updated 15 August 2022

What this trial tests

trial in Diabetes in 2,000 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 January 2024

22 June 2025

Quick facts

Lead sponsor	Willows Health
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 January 2023
Primary completion	1 January 2024
Estimated completion	22 June 2025
Sites	1 location across United Kingdom

Conditions studied

Diabetes — all drugs for Diabetes →
Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Cancer — all drugs for Cancer →
Bowel Disease — all drugs for Bowel Disease →

Sponsor

Willows Health

Who can join

18 and older, any sex, with Diabetes or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop Nuclear Magnetic Resonance (NMR) spectroscopy in human clinical pathology. This is an instrument assessment study for point of care viability which will also result in enhanced patient care (pending their consent) in blood screenings and metabolic health data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05473325 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Willows Health
Last refreshed: 15 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05473325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing